HURA - NASDAQ
TuHURA Biosciences, Inc.
$2.19
+5.8%TuHURA Biosciences, Inc. is a phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company is headquartered in Tampa, FL.
At a Glance
Live Snapshothura
Total Liabilities and Equity
Last Annual Value
27.35M
3-Year CAGR
22%
5-Year CAGR
15%
10-Year CAGR
16%
TuHURA Biosciences, Inc. Competitors Analysis of Total Liabilities and Equity
| Company | Total Liabilities and Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
TuHURA Biosciences, Inc. NASDAQ:HURA | 27.35M | 84.4% | 33.7% | 13.2% | |
 Cognition Therapeutics, Inc. NASDAQ:CGTX | 48.39M | 11.2% | -3.9% | N/A | |
 Seer, Inc. NASDAQ:SEER | 296.08M | -12.1% | -11.3% | N/A | |
 Context Therapeutics Inc. NASDAQ:CNTX | 68.49M | 62.2% | 5.9% | N/A | |
 Ovid Therapeutics Inc. NASDAQ:OVID | 150.93M | 1.6% | -4.9% | 11.0% | |
 Armata Pharmaceuticals, Inc. AMEX:ARMP | 76.88M | -7.9% | 2.0% | 15.5% | |
 Inovio Pharmaceuticals, Inc. NASDAQ:INO | 74.31M | -24.2% | -31.6% | -8.1% | |
 Seres Therapeutics, Inc. NASDAQ:MCRB | 138.19M | -27.2% | -17.2% | -6.6% | |
 Agenus Inc. NASDAQ:AGEN | 226.80M | -10.3% | -13.4% | 3.7% | |
 Acumen Pharmaceuticals, Inc. NASDAQ:ABOS | 122.83M | -26.6% | -11.8% | N/A | |
 VistaGen Therapeutics, Inc. NASDAQ:VTGN | 84.34M | 58.7% | -4.9% | 56.0% |
TuHURA Biosciences, Inc. Fair Value Envelope
Related Guides
Continue your HURA research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.